"your virtually asking them to publicize any and all

New Post Public Reply Private Reply Replies (2) Message Board
thesmalls C-Mac2 #10475
"your virtually asking them to publicize any and all forecasting models they may or may not even have in a very limited capacity. until they know the capture rate of the ever increasing RFQs in addition to other POTENTIAL streams of revenue what you are asking for is not possible to disclose. not to mention doing so could put them at a competitive disadvantage."

first - the company has already blatantly and repeatedly publicized its competitive advantage - we already know it and that is why those that i converse with frequently invested and have remained invested:

-chinese mfg which provides leverage on offsets - 20-30% instant cost reduction
-NAVAIR certification
-speed to market on orders drastically under competition (from 32-50 weeks down to as low as 4)
-competitive capacity is strained
-competitive landscape is complacent.

this is not unknown as they say it rather upfront to their potential investors and bankers in the2014 and 2015 plans (below is excerpted from 2015 plan):


"Competition
The Company is the only manufacturer of SAE-­‐AS certified aircraft component parts in China. Imported parts in China are subject to 24% import tax and duty. The Company’s management has excellent and currently ongoing working relationships with Boeing, Airbus and Embraer.

Neither Minebea nor RBC has made inroads into China from a manufacturing perspective for these parts, nor is it likely that they will anytime in the near future. The standoff over the islands known as Senkaku in Japan and Diaoyu in China is tense, with territorial claims escalating
on a daily basis. This adds to the already tenuous relationship caused by Japan’s refusal to acknowledge its wartime past to the satisfaction of China. Minebea does have plants in Shanghai and Zhuhai, but these facilities produce relatively easy to make ball bearings, DC motors, fan motors and PC keyboard parts. RBC, self-­‐ admittedly, has no aspirations to break into China, with recent growth attributed to acquisitions in the U.S. and U.K.

Moreover, neither manufacturer has the incentive to ramp up production to meet market demand, as both Minebea and RBC are satisfied with their respective market shares and are historically disinclined to investing in capital equipment or upgrading facilities. Their logic is simple: it’s a gravy train that we haven’t changed in 30 years; why do anything when all we have to do is raise prices and extend lead times?

This take-­‐it-­‐or-­‐leave-­‐it attitude leaves the market wide open for an aggressive new player. From the start, the Company will be able to:

• Deliver orders in as short a time as four weeks (versus 32-­‐52)
• Help Boeing, Airbus and Embraer meet offset obligations to China ($17 billion due and payable)
• Sole source to China-­‐based airlines and MROs at price points a minimum of 24% less than what they’re paying now
• Do all of the above while maintaining margins of 70%

Pricing Strategy

In regards to export sales, the Company plans to build a tiered global pricing model based on prevailing prices that will avoid a price war with Minebea and RBC. This strategy will:
• Allow our competitors to keep current prices at or near what they’re charging now
• Permit the Company to charge market prices, with a deep spread to maneuver for large orders
• Maintain the status quo: the Company, in effect, is not taking market share away from Minebea and RBC. Instead, it’s taking advantage of de novo business and offset markets in China
• Anticipated average unit selling price: $167

Significantly, this strategy will give the Company the option in three to five years to aggressively carve out global market share, at-­‐will, based on price. By not “rocking the boat” at the onset, the Company will build a sales and manufacturing advantage from which Minebea and RBC will find tough to counter, as both Minebea and RBC are running at full capacity with equipment over two decades old. "

so - there is no competitive disadvantage to be had by releasing such numbers - it is already out there in black and white.

second - per my prior post - they ALREADY forecasted in specific detail a 5 year revenue plan when capture rates weren't known and revenue operations hadn't even begun. now that they ARE revenue producing and the SLAs have some apparent teeth (according to IR), they should be in a better position to revenue forecast than they were a year ago. if the prior revenue stream was heavily dependent on expected acquisitions and thus more linear to project - say so.no one is going to crucify mgmt for changing course to a more viable, revenue generating (and cash saving) manner even if the acceleration curve isnt as robust. the company gave a forecast from $4.2 to $149 MM over 5 years (per chart in 2015 plan). if they are or are not going to be able to still ramp up that fast does not change the fact that the competitors are content with the status quo and cant ramp up or are going to dedicate the capital to revamp an aging fleet to do so (per strategy notes).

third - OS wasnt 1.8BB (or 1.9BB) due to a 700-800MM shares "error" that Bill took responsibility for earlier this year. but there is communication from him with those numbers when he was specifically talking about reducing OS by 1.8BB shares from where it started in 2015 (around 3.5BB). there was also talk of another 800MM beyond original 1.8BB that would have put share count around 1-1.2BB. there are numerous posts on OS in early 2016 around those numbers from several shareholders doing future PPS valuations based on his comments surrounding buyback and future OS.

fourth - IRMuse called/referred to me as a basher in a series of tweets when referencing specific posts of mine on here. i have the screenshots of the tweets. they were absurd.

so - in light of the above - what is specific disadvantage/competitive reasoning for NOT updating new 5 year revenue plan even if it is a series of ranges vs the detail provided in 2015? further - what is the damage to PPS/credibility by NOT doing so?

finally - as far as the golden question - cash flow right now is king for existing shareholders. company has 1-1.1BB in shares left before having to increase AS or doing a R/s (which they have been adamant that they will not do). at a 50% discount to current price - that is only $350K if they use up all of it. that does not take into consideration the death spiral that convertible debt would bring in which the price would quickly spiral back down to 0.0001-0.0002 with the aggressive shorting and covering and the discount to market the financiers would enjoy in the process. for $4.2MM in Y1 revenues - company projects $1.5MM in labor and material costs and production overhead alone. granted, the SLA structure shifts many of those costs/burdens off of $TPAC which make them extremely advantageous in the short term cash crunch but the company still has significant overhead and material costs ramping up on the other revenue streams. where does that money come from without a robust, immediate increase in revenues? right now they have $109K of a projected $4.2MM.

i realize most of these boards dont go into any depth or detail in reasoning/debate but if there are serious, long term holders that are concerned with cash flow and revenue ramp up like i am - i would like to engage them in thought and see where the above is askew. more importantly, i would like the company to just update the current plan relative to the last two years and put the speculation and assumptions to bed with concrete numbers backed up by current revenue producing streams in place right now and timelines for others to commence on the SLA front.

though i do not appear to be on their Christmas card list at the moment, i welcome constructive dialogue with IR on the topic as well.

Trans-Pacific Aerospace (TPAC) Stock Research Links

TPAC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TilePix Expands into Walmart with Nail-Free Decor Launch

Updated Category News Views 0

TilePix Makes Big Moves with Walmart TilePix is launching their new line of nail-free wall décor at Walmart—this ain’t your grandma’s wall art. This company's bringing their magnetic, nail-free wizardry to retail stores nationwide for the first time, and they’ve chosen a real heavyweight partner—Walmart. What comes in the package? Well, they’re dealing in...

Continue Reading
AI-Designed Antivirals: A Brave New World

Updated Category News Views 4

Pushing the Boundaries with AI in Drug Discovery It seems some smart folks over in South Korea are giving the pharma game a fresh twist, pitting artificial intelligence against viral invaders in a newfangled brawl. Professors from Korea University have managed to blend AI's computing prowess with good ol' lab doggedness to sniff out potential antiviral compounds. The...

Continue Reading
Ama La Vida's New Coaching: More Than a Financial Plan

Updated Category News Views 2

Breaking the Retirement Myth Retirement ain't just about sailing off into the sunset with a fat wallet. What happens when the honeymoon period of the "golden years" ends and you're left pacing the floorboards, unsure of what comes next? Enter Ama La Vida's fresh approach to retirement coaching, tackling the side of retirement that's rarely spoken about: identity,...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 35

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Costa Rican Firms Chase Growth at SIAL Paris 2026

Updated Category News Views 0

Chasing Growth in Paris: Costa Rica's Bold Move When it comes to playing the global field, Costa Rica isn't just sitting back; they're on the move. Picture this: PROCOMER, along with 18 standout companies, landed smack dab in the grand hustle and bustle of SIAL Paris 2026. This isn't some leisurely stroll—it's a calculated sprint toward expanding their reach across...

Continue Reading
Noé Hinojosa Jr. Honored for Leadership in Business

Updated Category News Views 1

From Bonds to Ballgames: Hinojosa's Impact Listen up, because this one’s more than just another accolade on a shelf. Noé Hinojosa Jr., a big gun over at TRB Securities, is getting the 2026 Hispanic Business Salute Award, and it's a doozy. Awarded by all the big wigs—UPS, NBC 5, Telemundo 39, and the Dallas Cowboys—this isn't a small pat on the back. It's a full-on...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 46

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 50

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading
Clean Power Alliance's Bond Deal Secures $91M Savings

Updated Category News Views 0

CPA Triumphs Yet Again With Bond Savings I'll tell you, the Clean Power Alliance (CPA) just hit the jackpot again. We're talking a $1.4 billion energy prepayment bond deal that locks in a whopping $91.1 million in savings over the next seven years. Not bad, huh? A Closer Look at the Numbers CPA's charm—besides being the top green power supplier in the U.S.—is spinning...

Continue Reading
Match2 Enhances HR Tech: Unified Talent Profile System

Updated Category News Views 7

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

Continue Reading

Top 5 Most Recently Viewed Articles

First Trust Mortgage Income Fund Announces Monthly Dividend

Updated Category News Views 43

First Trust Mortgage Income Fund's Monthly Distribution Announcement First Trust Mortgage Income Fund (NYSE: FMY) has declared its upcoming monthly common share distribution, marking an important date for its shareholders. The distribution set at $0.075 per share is payable soon, showing the Fund's commitment to providing consistent returns. Details About the Distribution...

Continue Reading
Akeso's 2024 Annual Report: Innovations in Bispecific Therapies

Updated Category News Views 718

Revolutionizing Cancer Treatment Through Innovation Akeso Inc. has announced its annual results for 2024, showcasing major achievements in biotechnology innovation. The company has focused on developing cutting-edge therapies, particularly in bispecific antibodies, aimed at transforming the treatment landscape for various cancers. Key Accolades and Advancements Key...

Continue Reading
Rona Therapeutics Receives Approval for RN1871 siRNA Treatment

Updated Category News Views 395

Rona Therapeutics Makes Significant Strides in Hypertension Treatment Rona Therapeutics, a biotechnology leader in RNA-targeted therapies, has achieved an impressive milestone with the approval of its Investigational New Drug (IND) application for RN1871 by China's National Medical Products Administration (NMPA). This innovative small interfering RNA (siRNA) drug is...

Continue Reading
Fleet Management Market Growth Forecast of USD 52.23 Billion

Updated Category News Views 150

Understanding Fleet Management Market Evolution The global fleet management market is poised for significant growth, expected to expand by USD 52.23 billion between 2025 and 2029. This growth is primarily fueled by the surge in e-commerce and the pressing need for last-mile delivery solutions. As industries continue to evolve, the integration of technology is transforming...

Continue Reading
Projected Growth and Challenges in the Anisole Market by 2033

Updated Category News Views 105

Understanding the Global Anisole Market Trends The global anisole market has been on a robust growth trajectory. Valued at approximately US$ 98.78 million as of recent estimates, it is poised to reach a remarkable US$ 165.48 million by 2033, with a compound annual growth rate (CAGR) of 5.9% from 2025 onwards. This upward trend indicates a significant demand for anisole...

Continue Reading